Low Skeletal Muscle Mass and Clinical Outcomes in Chronic Obstructive Pulmonary Disease

• Published in: Tuberculosis and respiratory diseases Vol. 86; no. 4; pp. 272 - 283
• Main Authors: Yong Jun Choi, Hye Jung Park, Jae Hwa Cho, Min Kwang Byun
• Format: Journal Article
• Language: Korean
• Published: 대한결핵 및 호흡기학회 01.10.2023
• Subjects: Chronic Obstructive Pulmonary Disease; Exacerbation; Mortality; Sarcopenia; Exacerbation; Sarcopenia; Chronic Obstructive Pulmonary Disease; Mortality
• ISSN: 1738-3536; 2005-6184

Background: In patients with chronic obstructive pulmonary disease (COPD), decreased muscle mass is a frequently encountered comorbidity in clinical practice. However, the evaluation of muscle mass in patients with COPD in real-world practice is rare. Methods: We retrospectively reviewed the electronic medical records of all patients with COPD who underwent bioelectrical impedance analysis at least once between January 2011 and December 2021 in three hospitals. Then, we analyzed the performance rate of muscle mass measurement in the patients and the correlation between muscle mass, clinical parameters, and COPD prognosis. Results: Among the 24,502 patients with COPD, only 270 (1.1%) underwent muscle mass measurements. The total skeletal muscle mass index was significantly correlated with albumin, alanine transaminase, and creatinine to cystatin C ratio in patients with COPD (r=0.1614, p=0.011; r=0.2112, p=0.001; and r=0.3671, p=0.001, respectively). Acute exacerbation of COPD (AE COPD) was significantly correlated with muscle mass, especially the truncal skeletal muscle mass index (TSMI) in males (r=-0.196, p=0.007). In the multivariate analysis, TSMI and cystatin C were significant risk factors for AE COPD (hazard ratio, 0.200 [95% confidence interval, CI, 0.048 to 0.838] and 4.990 [95% CI, 1.070 to 23.278], respectively). Conclusion: Low muscle mass negatively affects the clinical outcomes in patients with COPD. Despite its clinical significance, muscle mass measurement is performed in a small proportion of patients with COPD. Therefore, protocols and guidelines for the screening of sarcopenia in patients with COPD should be established.